Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02922257
Other study ID # FKBP5-700
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 2016
Est. completion date October 30, 2018

Study information

Verified date January 2019
Source Corcept Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.


Description:

This study will investigate the potential for FK506 binding protein 5 (FKBP5) (and other gene expression markers, for example pentraxin 3 [PTX-3], serum/glucocorticoid regulated kinase 1 [SGK1], and glycogen synthase kinase 3 beta [GSK3b]) to be developed as a biomarker for use in diagnosis of Cushing's syndrome, assessment of effectiveness of medical or surgical treatment, and detection of relapse of endogenous Cushing's syndrome after surgery.

The primary study hypothesis is that FKBP5 levels are elevated in patients with Cushing's syndrome, and these levels decrease after successful surgical treatment.

This is a non-randomized specimen collection study with pre- and post-surgery follow-up periods. This study will be performed in patients with adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome scheduled for curative surgery and followed until relapse of endogenous Cushing's syndrome or up to 3 years post-surgery. No study medication will be given.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date October 30, 2018
Est. primary completion date October 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age.

- Has a documented diagnosis of ACTH-dependent, endogenous Cushing's syndrome and is scheduled for curative surgery.

- Must be able to comprehend and sign an approved Informed Consent Form (ICF) and other applicable study enrollment documents.

Exclusion Criteria:

- Plans for pre-operative and/or intra-operative use of glucocorticoid ("steroid cover").

- Use any of the following treatments for Cushing's syndrome, as specified:

- 4 weeks prior to first specimen collection and/or during the study period.

- Adrenostatic medications (metyrapone, ketoconazole, fluconazole, aminoglutethimide, LCI699 or etomidate etc).

- Short-acting somatostatin analogs (octreotide, pasireotide).

- 6 weeks prior to first specimen collection and/or during the study period.

o Mifepristone.

- 8 weeks prior to first specimen collection and/or during the study period.

o Neuromodulator drugs that act at the hypothalamic-pituitary level: serotonin antagonists (cyproheptadine, ketanserin, retanserin), dopamine agonists (bromocriptine, cabergoline), gamma-aminobutyric acid agonists (sodium valproate), and somatostatin receptor ligands (octreotide long-acting release [LAR], pasireotide LAR, lanreotide).

- Concomitant use of the following due to their potential to stimulate the expression of FKBP5:

- Testosterone or other steroid hormone analogues.

- Oral contraceptives or hormonal replacement therapy.

- History of illness that the Principal Investigator (PI) considers could interfere with or affect the conduct, results, and/or completion of the clinical trial.

- Pregnancy or breastfeeding.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Corcept Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gene expression levels Change in FKBP5 expression levels from baseline to after surgical treatment but prior to glucocorticoid replacement therapy three years
See also
  Status Clinical Trial Phase
Completed NCT02468193 - Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Phase 2
Recruiting NCT00457587 - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Completed NCT00006278 - Study of Cushing's Syndrome Not Related to ACTH Production N/A
Completed NCT00361777 - Diagnostic Performance of Screening Tests for Cushing s Syndrome
Completed NCT03606408 - Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 Phase 2
Completed NCT02663609 - Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Recruiting NCT01504555 - Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Phase 3
Active, not recruiting NCT00004343 - Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome N/A
Completed NCT01371565 - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome Phase 3
Terminated NCT00422201 - Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion Phase 2
Completed NCT00001180 - Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency N/A
Completed NCT02804750 - Study to Evaluate CORT125134 in Participants With Cushing's Syndrome Phase 2
Completed NCT00936741 - An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome Phase 3
Recruiting NCT00004334 - Study of Depression, Peptides, and Steroids in Cushing's Syndrome N/A
Completed NCT03817840 - Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
Completed NCT01959711 - Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Phase 4
Completed NCT05633953 - Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Completed NCT02889224 - In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man N/A
Terminated NCT00796783 - A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia N/A
Recruiting NCT02019706 - Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome Phase 2